Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 2COVID-19 2Skin Neoplasms 1Respiratory Sounds 1Respiratory Distress Syndrome 1Pneumonia, Viral 1Pharmacokinetics 1Neoplasms 1Lymphoma, Follicular 1Cytokine Release Syndrome 1Crohn Disease 1Bronchiolitis Obliterans Syndrome 1Asthma 1Adenomatous Polyposis Coli 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Azithromycin × Clear all
NCT04341207 2020-04-10

ONCOVID

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown
1,000 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡